Invest in intelligence that delivers

Gastroenterologists Report Challenges Treating Eosinophilic Esophagitis as New Therapies Inch Closer to FDA Approval

A high percentage of undiagnosed patients and difficulties with treatment adherence among this mostly younger male patient population could be addressed by the entrance of one or more FDA-approved therapies in the next year  EXTON, Pa., November 16, 2021 /PRNewswire/ — Spherix recently surveyed 101 US gastroenterologists and followed up with ten qualitative interviews (including four with […]

Fueled by Growing Demand, Spherix Global Insights Introduces Ophthalmology to Expert Suite of Independent Market Research and Intelligence Services

The new addition ties Spherix’s unique approach to syndicated research to a highly dynamic market, filling the white space for pharma stakeholders in ophthalmology EXTON, Pa., November 11, 2021 /PRNewswire/ — Spherix Global Insights is a recognized market intelligence firm providing independent coverage of select specialty markets. This week, the company officially cut the ribbon […]

Ocrevus Still Top Therapy for Progressive MS Forms, Report Finds

From: Multiple Sclerosis News Today By: Marisa Wexler MS   Ocrevus (ocrelizumab) continues to be the most commonly prescribed therapy for progressive forms of multiple sclerosis (MS), including primary progressive MS (PPMS) and secondary progressive MS (SPMS), according to an analysis from the market intelligence firm Spherix Global Insights. However, other therapies are “gaining traction” among SPMS patients, the report finds…(read more)

Genentech’s Trailblazing Ocrevus Maintains Leading Position in the Progressive Multiple Sclerosis Space, But Emerging Bruton’s Tyrosine Kinase Inhibitors Could Threaten Its Long-Term Dominance

New patient-level data show that newer market entrants, such as BMS’ Zeposia and Novartis’ Kesimpta, are gaining traction in the US treatment algorithm   EXTON, Pa., November 4, 2021/PRNewswire/ – Although the population of multiple sclerosis (MS) patients with progressive disease remains underserved, several recent approvals for relapsing MS (RMS), which includes active secondary progressive […]

Novel Agents in Systemic Lupus Erythematosus (AstraZeneca’s anifrolumab) and Lupus Nephritis (Aurinia Pharmaceutical’s voclosporin and GSK’s belimumab) Introduce Paradigm Shifts

New launch tracking reports and patient audit data show early excitement and ample opportunity for the latest approvals as well as several pipeline agents (including Eli Lilly’s baricitinib in SLE and Roche-Genentech’s obinutuzumab in LN) garnering high interest among rheumatologists and nephrologists November 4, 2021, EXTON, PA – After nearly a decade of stagnant innovation […]

Spherix Global Insights Recognized as One of Greater Philadelphia’s Fastest Growing Companies for Third Year in a Row

    The Philadelphia Business Journal and the Philadelphia100® Forum announce this year’s list of top companies in the area EXTON, Pa., November 3, 2021 ― In their third year of eligibility, Spherix Global Insights, a market intelligence firm focusing on dermatology, gastroenterology, nephrology, neurology, ophthalmology, and rheumatology markets, is proud to be recognized as […]

Disparities in Kidney Care: Where Care Needs to Be Equal

Authors: Meghan Staudt, Skylar Malone, Tucker Hurtado BACKGROUND: Disparities in kidney care are widespread and gaining more attention. This research focuses on care differences that existed between home hemodialysis (HHD) and in-center hemodialysis (ICHD) patient from 2017 to 2020. METHODS: Using a HIPAA-compliant, online chart review tool, nephrologists submitted de-identified clinical and non-clinical demographic information […]

The New Era of COVID-19: The Rise of Telehealth, Trends to Home Dialysis, and the “New Normal”

Authors: Charisse Pearson Bey, Tucker Hurtado, and Jennifer Robinson   BACKGROUND: The objective of this study was to evaluate the impact of the COVID-19 pandemic to help conceptualize how patient care delivery, pharmaceutical representative interactions, conferences, and dialysis care may evolve. METHODS: Data was conducted between March 20, 2020 – March 31, 2021, providing coverage […]